XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Strategic Agreements (Details) - USD ($)
shares in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2022
Jul. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Jan. 31, 2020
Dec. 31, 2019
Nov. 30, 2019
Apr. 30, 2018
Feb. 28, 2018
Mar. 31, 2017
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                         $ 0 $ 250,000    
Total revenue                     $ 0 $ 0 10,000,000 0    
License fee                     25,000 25,000 75,000 75,000    
Accrued expenses                     4,136,330   4,136,330   $ 3,136,244  
Microchips Biotech, Inc.                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Asset acquisition, contingent consideration                               $ 50,000
Common stock issued to microchips capital stock holders (in shares)     700                          
Current portion of contingent consideration       $ 1,000,000     $ 1,000,000                  
Potential additional consideration payable       1,250,000                        
Accrued expenses                     250,000   250,000   250,000  
Cash paid to stockholders' representative     $ 75,000                          
Payment of additional consideration       $ 1,250,000                 46,500,000      
Microchips Biotech, Inc. | Common stock                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Common stock issued to microchips capital stock holders (in shares)             3,000                  
Microchips Biotech, Inc. | Upon Achievement of Specified Development and Regulatory Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payments             $ 46,500,000                  
Current portion of contingent consideration             $ 55,000,000                  
ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payments                   $ 2,500,000            
Maximum | ADVA Tec Agreement                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Percentage of royalty rate                   10.00%            
Maximum | ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payments                   $ 14,600,000            
Minimum | ADVA Tec Agreement                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Percentage of royalty rate                   1.00%            
MilanaPharm | Upon Achievement of Specified Development and Regulatory Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                         $ 50,000,000      
Bayer Healthcare License Agreement                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock         $ 310,000,000                      
Upfront license fee paid         1,000,000                      
Total revenue         $ 20,000,000                      
Initial term of license agreement         15 years                      
Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payments term                   3 years            
Milestone payments                   $ 20,000,000            
Licensing Agreements | MilanaPharm                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                           1,000,000 250,000  
License fee           $ 235,000                    
License fee to be paid upon contingency                               110,000
Royalty agreement term                         10 years      
License agreement termination periodic discontinued sale of product           60 days                    
License agreement termination period due to performance failure           120 days                    
Certain clinical and regulatory development milestone payments           90 days                    
Licensing Agreements | MilanaPharm | Upon Achieving Certain Development Milestones | Maximum                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock           $ 300,000                    
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                             750,000 100,000
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Upon Achievement of Specified Development and Regulatory Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                             $ 200,000  
Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Maximum                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                         $ 500,000      
Licensing Agreements | MilanaPharm | Licensed Product or Process for Vaginal or Urological Use                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                         250,000      
Assignment Agreement                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
License fee           512,500                    
Assignment Agreement | Hammock Pharmaceuticals, Inc                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
License fee to be paid upon contingency                               $ 137,500
Assignment Agreement | Hammock Pharmaceuticals, Inc | Upon Achieving Certain Clinical and Regulatory Development Milestones | Maximum                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock           $ 1,100,000                    
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Percentage of rights to inventions by employees under license agreement                 50.00%              
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                 $ 18,000,000              
Milestone additional payments, contingent amount                 10,000,000              
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                 500,000              
Milestone additional payments, contingent amount                 2,000,000              
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Maximum                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                 100,000,000              
Milestone additional payments, contingent amount                 125,000,000              
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Minimum                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                 10,000,000              
Milestone additional payments, contingent amount                 $ 10,000,000              
Juniper Pharmaceuticals, Inc                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Upfront license fee paid               $ 250,000                
Potential annual license maintenance fee, payments in year one               50,000                
Potential annual license maintenance fee payments, thereafter               100,000                
Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Maximum potential milestone payments               13,500,000                
Juniper Pharmaceuticals, Inc | Sales Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Maximum potential milestone payments               $ 30,300,000                
Hennepin License Agreement | Clinical and Regulatory Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Maximum potential milestone payments $ 6,250,000                              
Hennepin License Agreement | Sales Milestones                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Maximum potential milestone payments $ 45,000,000                              
Organon                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Upfront license fee paid   $ 10,000,000                            
Milestone payment paid in common stock                         182,500,000      
First commercial sale amount                         2,500,000      
Sales based milestones amount                     $ 180,000,000   $ 180,000,000      
Milestone payments term                         10 years      
Catalent and MilanaPharm                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Annual maintenance fee                       100,000        
Net amount payable     $ 900,000                 900,000   $ 900,000    
Catalent and MilanaPharm | Licensing Agreements                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Milestone payment paid in common stock                       $ 1,000,000